These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17593022)

  • 1. A strategic framework for novel drug development in multiple myeloma.
    Anderson KC; Hannah AL; Pazdur R; Farrell AT
    Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
    [No Abstract]   [Full Text] [Related]  

  • 2. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 4. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trials: misleading and unreliable.
    Stewart DJ
    J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trials.
    Farrington P; Miller E
    Methods Mol Med; 2003; 87():335-52. PubMed ID: 12958466
    [No Abstract]   [Full Text] [Related]  

  • 7. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 9. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trial designs for multiple myeloma.
    Hoering A; Crowley J
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology-driven phase II trials: what is the optimal model for molecular selection?
    Andre F; Delaloge S; Soria JC
    J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
    [No Abstract]   [Full Text] [Related]  

  • 15. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 16. [Phases 0, 1 and 2 oncology clinical trials: current questions].
    Penel N; Fournier C; Stéphanie C
    Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?
    Giralt S; Stadtmauer E; McCarthy P
    Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S30-2. PubMed ID: 21195307
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
    Mooney MM; Schoenfeldt M
    Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice.
    SanMiguel J; Facon T; Cavo M
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):s4-s10. PubMed ID: 18567204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.